The Effect of Raltegravir Intensification on Low-level Residual Viremia in HIV-Infected Patients on Antiretroviral Therapy: A Randomized Controlled Trial

Short‐Course Raltegravir Intensification Does Not Reduce Persistent Low‐Level Viremia in Patients with HIV‐1 Suppression during Receipt of Combination Antiretroviral Therapy

(2010) D. McMahon et al.   CLINICAL INFECTIOUS DISEASES

HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects

(2010) Maria J Buzón et al.   NATURE MEDICINE

Role of viral replication, antiretroviral therapy, and immunodeficiency in HIV-associated atherosclerosis

(2009) Priscilla Y Hsue et al.   AIDS

Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial

(2009) Jeffrey L Lennox et al.   LANCET

Understanding HIV-1 latency provides clues for the eradication of long-term reservoirs

(2009) Mayte Coiras et al.   NATURE REVIEWS MICROBIOLOGY

Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy

(2009) J. B. Dinoso et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The Challenge of Finding a Cure for HIV Infection

(2009) D. D. Richman et al.   SCIENCE

Raltegravir with Optimized Background Therapy for Resistant HIV-1 Infection

(2008) Roy T. Steigbigel et al.   NEW ENGLAND JOURNAL OF MEDICINE

Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy

(2008) S. Palmer et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA